SCHEMBL5540564

SCHEMBL5540564

O=[C]OCc1ccc(-c2csnn2)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.55
RAB9A P51151 4/20 0.55
NPC1 O15118 3/20 0.55
MEN1 O00255 2/20 0.55
POLB P06746 2/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
NOTUM Q6P988 1/20 0.49
MGLL Q99685 2/20 0.43
CDC25A P30304 1/20 0.43
CDC25B P30305 1/20 0.43
CDC25C P30307 1/20 0.43
PTPN1 P18031 2/20 0.42
MAPT P10636 3/20 0.41
KDM4E B2RXH2 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5541973 0.82 KMT2A (0.47) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL18216639 0.79 KMT2A (0.59) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL5540568 0.78 KMT2A (0.55) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL95791 0.76 KMT2A (0.58) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL19900671 0.75 KMT2A (0.78) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL18213807 0.75 KMT2A (0.55) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL219769 0.73 KMT2A (0.58) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL4573216 0.73 KMT2A (0.58) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL632993 0.73 KMT2A (0.58) KMT2ARAB9ANPC1MEN1POLB
SCHEMBL95792 0.73 KMT2A (0.58) KMT2ARAB9ANPC1MEN1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
CN-1705670-A 2, 3-dihydro-6-nitroimidazo [2, 1-b ] oxazole compounds OTSUKA PHARMA CO LTD (JP) 2005-12-07 CN disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 KMT2A 4267/4885RAB9A 2824/4885NPC1 2404/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.